Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ECOLAB INC.ECL · Entity 2954 | Director | September 30, 2026 | October 03, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director · President, CEO and Board Chair | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ECOLAB INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,089.19 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 131.17 · Balance 8,089.19 F1: Includes 10.74 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. |
| Common StockSEC Table I · non-derivative | Direct | 8,233.94 |
Reported balance
After 2026-09-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-30 · Grant · Acquired 144.75 · Balance 8,233.94 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 10.74 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.
WEST PHARMACEUTICAL SERVICES INC
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 6,986 |
Reported balance
After 2026-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 6,986 · Balance 6,986 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $254.34 · Expires 2036-03-01 | Direct | 16,630 |
Reported balance
After 2026-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-01 · Grant · Acquired 16,630 · Balance 16,630 F3: The stock option vests in four equal annual installments beginning on March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
F3: The stock option vests in four equal annual installments beginning on March 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 4, 2023 21:49 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 189.61 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006098 · form4-04042023_090430.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245.61 Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · derivative · entry 7 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,132 Underlying: Common Stock · 50,000 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,131 | $324.29 | $366,771.99 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 6 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,574.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $324.10 to $324.55, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 5,277 | $323.38 | $1,706,478.37 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 5 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,297.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $323.09 to $324.03, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 26,753 | $322.49 | $8,627,505.41 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,544.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $322.07 to $323.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 7,685 | $321.61 | $2,471,602.05 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,859.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $321.06 to $322.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 3,154 | $320.60 | $1,011,173.03 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,705.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $320.06 to $321.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 50,000 | $57.38 | $2,869,000.00 |
DisclosureSEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,705.0865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 29,872 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001792 · primarydocument.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,872 Underlying: Stock Options (Right to Buy) · 29,872 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14,783 | $306.68 | $4,533,650.44 |
DisclosureSEC source: 0001562180-23-001792 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,705.0865 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 22:27 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000118 · form4-01032023_100106.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56 Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · derivative · entry 8 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,132 Underlying: Common Stock · 50,000 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,100 | $241.46 | $265,610.95 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 7 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,922.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F8 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $241.33 to $241.56, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 9,682 | $240.73 | $2,330,774.97 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 6 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,022.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $240.29 to $241.27, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 10,752 | $239.70 | $2,577,224.29 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 5 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,704.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $239.26 to $240.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 6,312 | $238.83 | $1,507,474.76 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,456.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $238.26 to $239.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 9,408 | $237.67 | $2,235,976.78 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,768.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $237.255 to $238.21, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 6,746 | $236.95 | $1,598,456.60 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,176.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $236.255 to $237.245, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 50,000 | $57.38 | $2,869,000.00 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,922.0865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares reported were acquired by the Reporting Person from exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022. Read SEC document |
| March 10, 2022 Filed Mar 28, 2023 20:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GiftCommon Stock | 2,700 | $371.47 | $1,002,969.00 |
DisclosureSEC source: 0001562180-23-003146 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,874.0865 F1 · kind: This transaction represents a charitable gift donation to a private, non-profit educational institution for which Mr. Green received no compensatory benefit and subject to the requirement that the shares were not sold for 60 days by the recipient Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:51 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 31,088 | $0.00 Strike: $369.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001877 · primarydocument.xml · derivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,088 Underlying: Stock Options (Right to Buy) · 31,088 shares Expires 2032-02-22 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 22,104 | $369.13 | $8,159,249.52 |
DisclosureSEC source: 0001562180-22-001855 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,922.0865 F1 · shares: 2019 PSUs (PP18) award vesting net of taxes withheld Read SEC document |
| February 13, 2022 Filed Feb 14, 2022 22:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 85 | $391.20 | $33,252.00 |
DisclosureSEC source: 0001562180-22-001453 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,818.0865 F1 · shares: Shares withheld to cover taxes related to Bonus and incentive shares granted on February 13, 2018. Read SEC document |
| May 19, 2021 Filed Feb 11, 2022 11:15 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GiftCommon Stock | 3,150 | $325.00 | $1,023,750.00 |
DisclosureSEC source: 0001562180-22-001350 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,903.0865 F1 · kind: This transaction represents a charitable gift donation to a private, non-profit educational institution for which Mr. Green received no compensatory benefit and subject to the requirement that the shares were not sold for 60 days by the recipient Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 43,652 | $0.00 Strike: $274.29 | $0.00 |
DisclosureSEC source: 0001562180-21-001589 · primarydocument.xml · derivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,652 Underlying: Common Stock · 43,652 shares Expires 2031-02-23 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:32 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 17,767 | $272.65 | $4,844,172.55 |
DisclosureSEC source: 0001562180-21-001570 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,053.0865 F1 · shares: 2018 PSUs (PP17) award vesting net of taxes withheld Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 17:27 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 92 | $294.01 | $27,048.92 |
DisclosureSEC source: 0001562180-21-001185 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,286.0865 F1 · shares: Shares withheld to cover taxes related to Bonus and incentive shares granted on February 14, 2017. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:27 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 5 | $197.94 | $989.70 |
DisclosureSEC source: 0001562180-20-004305 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,378.0865 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 4/24/2020 Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 5,858 | $195.54 | $1,145,473.32 |
DisclosureSEC source: 0001562180-20-003192 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,373.0865 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 19:53 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 192 | $170.16 | $32,670.72 |
DisclosureSEC source: 0001562180-20-001642 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,231.0865 F1 · shares: Shares withheld to cover taxes related to Bonus and incentive shares granted on February 23, 2016. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 57,384 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001562180-20-001423 · primarydocument.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,384 Underlying: Common Stock · 57,384 shares Expires 2030-02-18 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 9,392 | $173.22 | $1,626,882.24 |
DisclosureSEC source: 0001562180-20-001423 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,423.0865 F1 · shares: 2017 PSUs (PP16) award vesting. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 85,680 | $102.51 Strike: $102.51 | $8,783,056.80 |
DisclosureSEC source: 0001562180-19-001218 · primarydocument.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,680 Underlying: Common Stock · 85,680 shares Expires 2029-02-19 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6,034 | $102.51 | $618,545.34 |
DisclosureSEC source: 0001562180-19-001218 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,031.0865 F1 · shares: 2016 PSUs (PP15) award vesting. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 21:20 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 7,716 | $92.00 | $709,872.00 |
DisclosureSEC source: 0001562180-18-001991 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,997.0865 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:35 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 87,720 | $89.64 Strike: $89.64 | $7,863,220.80 |
DisclosureSEC source: 0001562180-18-001147 · primarydocument.xml · derivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,720 Underlying: Common Stock · 87,720 shares Expires 2028-02-20 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/20/2019 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 9,836 | $93.00 | $914,748.00 |
DisclosureSEC source: 0001562180-18-001010 · primarydocument.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,713.0865 F2 · shares: 2015 PSU (PP14) award vesting Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,421 | $93.00 | $132,153.00 |
DisclosureSEC source: 0001562180-18-001010 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,877.0865 F1 · shares: Bonus & Incentive share grant Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 20:18 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 83,616 | $83.47 Strike: $83.47 | $6,979,427.52 |
DisclosureSEC source: 0001562180-17-000847 · primarydocument.xml · derivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,616 Underlying: Common Stock · 83,616 shares Expires 2027-02-21 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/21/2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6,225 | $86.93 | $541,139.25 |
DisclosureSEC source: 0001562180-17-000733 · primarydocument.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,456.0865 F3 · shares: Shares represent the portion of the Performance Share Unit Award granted in 2014 that have vested for period 13. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,540 | $86.93 | $133,872.20 |
DisclosureSEC source: 0001562180-17-000733 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,231.0865 F1 · shares: Bonus and incentive shares granted on 02/14/2017. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 19:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14.0553 | $84.83 | $1,192.31 |
DisclosureSEC source: 0001562180-17-000065 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 248.6299 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:53 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14.0885 | $84.63 | $1,192.31 |
DisclosureSEC source: 0001562180-16-003839 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 234.5746 Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 14:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14.7984 | $80.57 | $1,192.31 |
DisclosureSEC source: 0001562180-16-003665 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 220.4861 Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 15:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14.8778 | $80.14 | $1,192.31 |
DisclosureSEC source: 0001225208-16-042013 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 205.6877 Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 16:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 15.8152 | $75.39 | $1,192.31 |
DisclosureSEC source: 0001225208-16-041223 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 190.8098 Read SEC document |
| October 21, 2016 Filed Oct 24, 2016 14:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 16.6337 | $71.68 | $1,192.30 |
DisclosureSEC source: 0001225208-16-040696 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 174.9946 F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 11:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 15.8047 | $75.44 | $1,192.31 |
DisclosureSEC source: 0001225208-16-040306 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 158.2311 Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 16:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 16.4343 | $72.55 | $1,192.31 |
DisclosureSEC source: 0001225208-16-039646 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 142.4264 Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 12:57 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 14.8685 | $80.19 | $1,192.31 |
DisclosureSEC source: 0001225208-16-039216 · doc4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 125.9921 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.